Meet Inspiring Speakers and Experts at our 3000+ Global Conference Series Events with over 1000+ Conferences, 1000+ Symposiums
and 1000+ Workshops on Medical, Pharma, Engineering, Science, Technology and Business.

Explore and learn more about Conference Series : World's leading Event Organizer

Back

E Vigneshwaran

E Vigneshwaran

King Khalid University, KSA

Title: Pharmacoeconomics – A tool in formulary development

Biography

Biography: E Vigneshwaran

Abstract

Essential medicines list is the concept that satisfies the priority of healthcare needs and promotes rational use of medicines. The drugs which are present in the list should address the disease burden based on its prevalence at all levels of health care. It also serves as basis of drug formulary. Increased drug utilization, increased drug price, availability of number of drugs to single indication and limited budgets shows the need of formulary. Formulary is a continuous revised compilation of pharmaceuticals and related products started as simple list of available drugs, and then they evolved into a dynamic guide for an effective management of drug therapy by health care professionals in clinical applications. Decisions about drug selection are complex and are influenced not just by evidenced based criteria but also take into account of economical and therapeutic aspects of drug, and political, social and ethical values of community to which the decisions apply. Thus pharmacoeconomics (PE) can serve as one of the tool in drug selection process for an effective development of formulary, but it may require strong co-ordination between pharmacoeconomic expertise and health care professionals. Literatures also reported that use of PE information in creating formulary is limited due to various barriers. However, it must be used to manage limited health resources in the best way. Therefore more educational programs to the decision makers should be conducted to facilitate the use of such tool in developing formulary. Because current evidence suggests that pharmacoeconomic information is not widely used worldwide.